Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study

Aicha Ben Tekaya,1 Salma Mokaddem,2 Selma Athimini,3 Hela Kamoun,4 Ines Mahmoud,1 Leila Abdelmoula1

1Rheumatology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis
2Department of Physiology, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis
3Rheumatology Department, Mahmoud El Matri Hospital, Ariana
4Pulmonary Department, Abderrahmanen Mami Hospital, Faculty of Medicine de Tunis, University Tunis El Manar, Tunis, Tunisia

Background: The objective of this study was to assess clinical and imaging features of rheumatoid arthritis (RA) associated with interstitial lung disease (ILD), (RA-ILD) group, in comparison to RA without ILD (RA-C) and to identify the associated factors to ILD.

Methods: This was a retrospective comparative study (from June 2015 to March 2022) including RA patients aged ≥18 years. The RA-C control group was matched according to age (±2 years), gender, and RA duration (±2 years). General data, RA characteristics, ILD features, and treatment modalities were recorded. Statistical analysis was performed to determine the predictive factors of ILD.

Results: A total of 104 patients were included (52 RA-ILD and 52 RA-C); sex ratio was 0.36. Mean age was 66.3±11 years (RA-ILD) versus 65.6±10.8 years (RA-C) (p=0.72). In comparison to RA-C, RA-ILD patients were significantly higher smokers (p=0.01) and physically inactive (p=0.01). Regarding RA features, RA-ILD patients have significantly increased positive anti-citrullinated peptide antibody (ACPA) (p=0.01), ACPA rate (p<0.001), erosive disease (p<0.001), and disease activity score (p<0.001). Mean time to ILD diagnosis was 5.85±7.16 years. Chest high-resolution computed tomography (HRCT) patterns of disease were identified: nonspecific interstitial pneumonia (NSIP) (28.8%), usual interstitial pneumonia (UIP) (17.3%), organizing pneumonia (OP) (25%), acute interstitial pneumonia (13.5%), and respiratory bronchiolitis (3.8%). Multivariate analysis identified smoking, high baseline DAS28 (disease activity score 28) and ACPA positivity as predictive factors of ILD.

Conclusion: Our results confirmed the reported associated factors of ILD in RA (smoking, higher disease activity, ACPA positivity). Thus, we need to target the modifiable factors by supporting and educating RA patients to quit smoking and intensify disease modifying anti-rheumatoid drugs (DMARD) to reach remission.

Key words: Rheumatoid arthritis; interstitial lung disease; risk factors.
Introduction

Rheumatoid arthritis (RA) is the most prevalent rheumatic inflammatory disease [1]. Extraarticular features constitute the hallmark of the systemic character of the disease [2]. Thanks to modern imaging, interstitial lung disease (ILD) is going more described in RA. The reported prevalence of ILD associated with RA (RA-ILD) ranged between 20 and 50% [3,4]. ILD accounts for among the main causes of morbidity and mortality in RA [2]. Although the definition of ILD was based on histopathological criteria, diagnosis can be established nowadays using high-resolution computed tomography (HRCT) backed by pulmonary function and clinical symptoms [3]. Mastering its diagnosis and management features can significantly change the RA prognosis. However, specific predictive biomarkers of ILD are still lacking, and lead to delay diagnosis [4,5]. On the other hand, the role of disease-modifying antirheumatic drugs (DMARD)’s drug toxicity in the onset or worsening of ILD is also controversial [6,7]. Thus, early screening of RA patients for ILD is mandatory.

The objective of the study was to assess clinical and imaging features of RA-ILD patients in comparison to RA patients without ILD and to identify the associated factors to ILD.

Methods

Study design and population

This was a retrospective comparative study extended over a 7-year period (June 2015-March 2022). Patients aged ≥18 years and diagnosed with RA according to the American College of Rheumatology and European League of Rheumatology (ACR/EULAR) 2010 RA criteria were included [8]. Sample size was composed of 2 groups: RA-ILD group and control group of RA without ILD (RA-C). The control group (RA-C) was matched to RA-ILD patients according to gender, age (±2 years) and RA duration (±2 years). RA-ILD fulfilled the Clinical-Radiologic-Pathologic Diagnosis (New ATS/ERS Classification) [9]. ILD categories such as those drug-induced, associated with occupational or environmental exposure, collagen vascular disease, and granulomatous lung disorders were not included.

Data collection

General data were collected: age, gender, tuberculosis history, physical activity, smoking habits, anthropometric measures and the presence of concurrent comorbidities. Regular physical activity corresponded to at least 150 minutes a week of moderate-intensity physical activity [10]. RA characteristics including age at onset of RA, disease duration, extra-articular features, erosions/joint damage were assessed via X-ray, and serologic status: positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA), and their rate. Disease parameters were recorded at the diagnosis of ILD: number of nocturnal awakenings, morning stiffness duration, VAS pain, disease activity score (DAS), and C-reactive protein (CRP).

ILD features at diagnosis (baseline) were noted: diagnosis delay since onset of, RA clinical symptoms, spirometry, imaging findings (chest radiographs, chest HRCT), and ILD classification: usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), acute interstitial pneumonia (AIP), respiratory bronchiolitis, desquamative interstitial pneumonia (DIP), and lymphoid interstitial pneumonia (LIP). Therapeutic data were detailed: list of DMARD at diagnosis of ILD, and change in medication after ILD confirmation. The last evaluation of spirometry and HRCT was also recorded. We considered disease progression (deterioration) as: a decline of 15% in gas transfer from baseline and/or imaging worsening in follow up HRCT.

Statistical analysis

Statistical package for social sciences (SPSS) version 26.0 was used to perform statistical analysis. The quantitative variables were summarized as mean and standard deviation (SD). The qualitative variables were expressed as percentages and frequencies. Comparisons between quantitative variables were made using ANOVA test. The Chi-square test was used to analyse categorical data. Multivariate analysis with multiple logistic regression was performed to identify the predictive factors of ILD; odds ratio (OR), their 95% confidence intervals, and the significance level were reported. The level of significance was set at p<0.05.

Results

Patients’ and RA characteristics

A total of 104 patients were included (52 RA-ILD and 52 RA-C); 76(73%) were females in the 2 groups. Mean age was 66.3±11 years (RA-ILD) versus 65.6±10.8 years (RA-C), (p=0.72). In comparison to RA-C, RA-ILD patients were significantly higher current smoking (p=0.01) and physical inactivity (p=0.01). There was no significant statistical difference regarding to number of comorbidities between 2 groups (p=0.85). Patients’ characteristics were summarized in Table 1.

| Table 1. General data of the sample size (RA-ILD, RA-C). |
|---------------------------------|----------------|-------------|
| **RA-ILD**                      | **RA-C**       | **p**       |
| Sex ratio                       | 0.36           | 0.36        | -           |
| Mean age, years (±SD)           | 66.3 (±11)     | 65.6 (±10.8)| 0.72        |
| Smoking, n (%)                  | 19 (37)        | 7 (13)      | 0.01        |
| BMI, mean (±SD)                 | 27.5 (±6.04)   | 26.5 (±4.41)| 0.41        |
| Physical activity, n (%)        |                |             | 0.01        |
| Regular                         | 23 (55.7)      | 38 (73)     |             |
| Sedentary                       | 23 (44.3)      | 17 (27)     |             |
| Medical comorbidities           |                |             |             |
| Diabetes                        | 10 (19.2)      | 9 (17.3)    |             |
| Hypertension                    | 13 (25)        | 15 (28.8)   |             |
| Dysphagia                       | 2 (3.8)        | 4 (7.6)     |             |
| Cardiac comorbidities           | 1 (2)          | 2 (3.8)     |             |

RA, rheumatoid arthritis; ILD, interstitial lung disease; RA-C, control group; BMI, body mass index.
The mean age at onset of RA was 47.2±13.5 years (RA-ILD) versus 48±12.8 (RA-C), (p=0.76). Mean RA duration was 13.3±7.8 (RA-ILD) versus 12.2±7.4 (RA-C), (p=0.44). RA-ILD patients, in comparison to RA-C, have significantly increased positive ACPA (p=0.01), ACPA rate (p<0.001), erosive disease (p<0.001), extra-articular features (p=0.027), and Sjogren’s syndrome (p=0.021). Disease activity was significantly higher in the RA-ILD group in terms of VAS pain (p<0.001), number of nocturnal awakenings (p=0.033), morning stiffness duration (p<0.001), and DAS_{28} CRP (p<0.001). Table 2 represented RA features of the 2 groups.

**Interstitial lung disease**

Mean time to ILD diagnosis was 5.85 years±7.16; ILD preceded RA diagnosis in 4 patients. Baseline evaluation showed: breathlessness (44%), cough (23%), restrictive (75%)/obstructive (2%) patterns on spirometry, and peripheral reticular opacity (82.7%) on chest radiographs. Chest HRCT patterns of disease were identified: NSIP (28.8%), UIP (17.3%), organizing pneumonia (25%), acute interstitial pneumonia (13.5%), and respiratory bronchiolitis (3.8%). The last spirometry evaluation demonstrated worsening of restrictive disorder (55%), sustainability (26%), and improvement (19%).

Regarding treatment for ILD, 25% received glucocorticoids mean daily dose 9±3.4 mg (5-25)], 15% inhaled steroids, and 4% one course of cyclophosphamide 1 g. As for change in DMARD prescription: discontinuation MTX (24%), sulfasalazine (40%), and leflunomide (100%); switch from TNF inhibitors to rituximab (n=9), switch from csDMARD to rituximab (n=11), and prescription of tocilizumab (n=4). Assessment of last chest HCRT imaging recorded was detailed in Table 3.

**Predictive factors of RA-ILD**

Multivariate analysis identified smoking, high baseline DAS28 and ACPA positivity as predictive factors of ILD (Table 4).

**Discussion**

This study compared two RA patients with and without ILD. The 2 groups were comparable according to age (±2 years), sex and RA duration (±2 years). We highlighted that RA-ILD patients have significantly higher severe disease (erosive, high ACPA rate), and active disease (DAS_{28} patient reported outcomes).

ATS/ERS (American Thoracic Society/ European Respiratory Society) classification criteria are currently the most used for diagnosis, evaluation and follow up of ILD. These were initially established in 2000, reviewed in 2012 and more recently in 2018 [9,10]. They are based on a variety of arguments (history, clinical, imaging, spirometry and histology if necessary). In our study, HRCTs were assessed by expert radiologists, no one underwent a lung biopsy. NSIP was more common than OP and both were more

---

**Table 2. Comparative disease features between RA-ILD and RA-C.**

|                      | RA-ILD          | RA-C          | p    |
|----------------------|-----------------|---------------|------|
| Mean age of onset of RA, (years ±SD) | 47.2±13.5       | 48±12.8       | 0.76 |
| RA duration, (years ±SD)         | 13.3±7.8        | 12.2±7.4      | 0.44 |
| Positive ACPA, n (%)             | 44 (84.6)       | 32 (61.5)     | 0.01 |
| Mean ACPA rate at diagnosis, (U/ml ±SD) | 27±181         | 13±109        | <0.001 |
| Positive RF, n (%)               | 37 (71)         | 33 (64)       | 0.4  |
| Erosive disease, n (%)           | 50 (96)         | 34 (65)       | <0.001 |
| Mean DAS_{28} CRP ±SD            | 45±12.2         | 360±9.4       | <0.001 |
| Mean CRP, (mg) ±SD               | 40±13.3         | 31.3±26       | 0.18 |
| VAS pain ±SD                    | 7.16±1.37       | 4.1±1.68      | <0.001 |
| Nocturnal awakenings, n (%)      | 2.87 (1.3)      | 1 (1)         | 0.033|
| Mean morning stiffness, (min ±SD)| 92.2±7.4        | 18.3±20       | <0.001|
| AAL, n (%)                       | 6 (12)          | 1 (2)         | 0.11 |
| Coxitis, n (%)                   | 7 (13)          | 3 (5.8)       | 0.3  |
| Extra-articular features, n (%)  | 32 (100)        | 46 (88)       | 0.027|
| Ocular                           | 34 (65)         | 30 (58)       | 0.42 |
| Sjogren syndrome                 | 31 (60)         | 25 (46)       | 0.021|
| Renal                             | 3 (5.8)         | 6 (12)        | 0.49 |
| Cardiovascular                    | 6 (12)          | 3 (5.5)       | 0.49 |
| Osteoporosis                      | 22 (42)         | 6 (12)        | 0.5  |
| csDMARD                           | 38 (73)         | 43 (82)       |      |
| Methotrexate, n (%)               | 15 (29)         | 8 (27.5)      |      |
| Sulfasalazine, n (%)              | 1 (0.02)        | 0             |      |
| bDMARD                            | 6 (12)          | 8 (27.5)      |      |
| TNF inhibitors, n (%)             | 3 (5.8)         | 9 (17.3)      |      |
| Rituximab, n(%)                   | 2 (3.9)         | 2 (3.9)       |      |

RA, rheumatoid arthritis; ILD, interstitial lung disease; RA-C, control group; BMI, body mass index; ACPA, anti-citrullinated protein antibodies; RF, rheumatoid factor; DAS_{28}, disease activity index 28; CRP, c-reactive protein; VAS, visual analogue scale; AAL, atlantoaxial dislocation; csDMARD, synthetic disease modifying anti-rheumatoid drugs; bDMARD, biologic disease modifying anti-rheumatoid drugs.
common than UIP. This finding that was not in concordance with previous reports which described UIP as the most prevalent category of ILD [10,11].

Despite a good knowledge of the RA pathophysiological mechanisms, determining the RA-ILD predictive factors remains challenging. Male sex, advanced age, smoking status, ACPA positivity, DMARDs and high disease activity have all been suggested as putative risk factors [12-15].

A recent systematic review and meta-analysis including 29 records concluded that both the presence and higher titer of ACPA were suggested to be significantly associated with an increased risk of RA-ILD [4,11,16,17]. Pursuant to that, our results were in line with literature data: ACPA positivity and rate were significantly higher in RA-ILD than in RA without ILD, and the absence of ACPA was a protective factor from RA-ILD (OR=0.294; p=0.03).

In line with previous reports, smoking was identified in our work as a predictive factor of RA-ILD [18,19]. Smoking is the most studied predisposing factor for the occurrence of joint and extra-articular manifestations of RA [1]. Saag et al. showed an odds ratio of 3.8 was found with patients smoking over 25 pack-years for RA-ILD patients [20]. RA-specific autoimmunity antibodies may be triggered by external factors such as smoking to generate an immunological interaction in the lung tissues and leading to pulmonary damage such as ILD [19].

In our study, higher disease activity score was also a predictive factor of ILD. Interestingly, selection criteria of 2 groups, especially in terms of disease duration, allowed to avoid confounded factors. Many studies had showed association between higher disease activity and ILD [4,12,21,22], however the study design must be reviewed.

Demographic factors were not associated to ILD in our study as previously reported. In fact, advanced age was considered as a risk factor [14,15] and a predictor of mortality [23,24]. Male sex was also identified as a RA-ILD risk factor even though the female susceptibility for developing RA [25,26].

Despite new advances in RA treatment, the management of RA-ILD patients remains fairly vague. Unlike RA, no clear guidelines were established after ILD diagnosis. In our study, previous and current treatments were not associated with ILD occurrence or progression. These results are in accordance with literature data. Perez et al demonstrated that csDMARDs was not associated with spirocentigraphy, HRCT incomes in RA-ILD regardless the type of drugs [27].

Moreover, it has been hypothesized that MTX, the most commonly recommended treatment for RA in first line, can cause ILD as an adverse effect. This affirmation has been controversial over the past 10 years, proving that there was no further increased risk of ILD or respiratory failure with MTX. In accordance with these findings, a Danish nationwide population-based study found no increased risk with MTX at each the 1-, 5- or 10-years’ follow up [28]. Otherwise, a meta-analysis of 22 randomized controlled trials showed a small but increased risk of MTX compared with other DMARD or biologic agents for overall respiratory events but not for non-infectious pulmonary events [29].

A recent review published in 2021 had assessed treatment strategy in RA-ILD [30]. Authors concluded that csDMARDs still is used as first approach regardless their controversial role in ILD occurrence. Corticosteroids are the mainstay of therapy in ILD, particularly for cases of NSIP or OP where they may lead to potential clinical and imaging improvement. Similar to csDMARDs, controversy regarding TNF inhibitors is showing improvement and others demonstrating development or progression of ILD. The management approach still leaved to physician common sense and on a case-by-case basis. Among the drugs panel for RA, rituximab and abatacept demonstrated promising results better than other biologicals, such as TNF blockers, in terms often achieving stabil-

Table 3. ILD evolution in patients following treatment change.

| Drug | Not evaluated | Sustainability | Aggravation | Improvement | Total |
|------|--------------|----------------|-------------|-------------|-------|
| bDMARD | Rituximab | 5 (25%) | 6 (30%) | 2 (10%) | 7 (35%) | 20 |
| | Tocilizumab | 3 (50%) | 2 (33%) | 1 (17%) | 6 |
| | TNF inhibitor | 3 (20%) | 11 (73%) | 1 (7%) | 15 |
| CsDMARD | None | 4 | 0 | 6 | 0 | 10 |
| | Methotrexate | 9 (29%) | 8 (28%) | 5 (16%) | 9 (29%) | 31 |
| | Sulfasalazine | 1 (14%) | 2 (28%) | 3 (43%) | 1 (14%) | 7 |

bDMARD, biologic disease modifying anti-rheumatoid drugs; csDMARD, synthetic disease modifying anti-rheumatoid drugs.

Table 4. Predictive factors of interstitial lung disease.

| Variables | Modality | OR (CI at 95%) | p |
|-----------|----------|----------------|---|
| Intercept |          | 0.0423 (0.00458-0.300) | <0.01 |
| Smoking   | Yes      | 4.76 (1.52-16.8) | 0.01 |
| Physical activity | None | 1.90 (0.651-5.74) | 0.25 |
| | Regular | 0.364 (0.0885-1.33) | 0.14 |
| ACPA     | Positive | - | - |
| | Negative | 0.294 (0.0916-0.857) | 0.03 |
| DAS28 CRP | - | 2.13 (1.38-3.51) | <0.01 |

$R^2$ de Nagelkerke = 34.9%

OR, odds ratio; CI, confidence interval; ACPA, anti-citrullinated protein antibodies; DAS28, disease activity index 28; CRP, C-reactive protein.
lization and improvement of ILD in patients with RA [31].
In this work, results related to our population were mostly in concordance with studies and literature results and support other authors finding in matter of diagnosis, prognosis and management of ILD. Despite the restrict number of patients, our description may insure us that international recommendations are applicable to our population particularities.

However, this study has some limitations. The retrospective design did not allow to conclude about the causal relationship between RA and ILD. Further longitudinal cohort studies involving larger samples are necessary to confirm our results. Second, the time of the last evaluation of spirometry and HCRT was not the same. Interestingly, our patients were homogenous in terms of age, gender and disease duration which can eliminate some interpretation bias.

**Conclusion**

RA-ILD remains a real clinical and therapeutic challenge and it is associated with poor survival rate. This study tried to highlight the importance of disease’s assessment to predict prognosis and improve patient management: we discerned smoking, positive ACPA and high disease activity as the most common predictive factors of ILD. Despite a large variety of treatment, progression of ILD on HRCT was seen in 18,2% of cases in this study. Improvements in RA therapy in recent years did help to reduce mortality of lung affection.

**References**

1. Bendstrup E, Moller J, Kronborg-White S, Prior TS, Hyldgaard C. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med 2019;8:2038.
2. Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol 2021;40:1211-20.
3. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 2020;9:880.
4. Chen J, Chen Y, Liu D, Lin Y, Zhu L, Song S, et al. Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease. Sci Rep 2022;12:9469.
5. Moua T, Zamora Martinez AC, Baqr M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014;15:154.
6. Duarte AC, Porter JC, Leandro MJ. The lung in a cohort of rheumatoid arthritis patients - an overview of different types of involvement and treatment. Rheumatology 2019;58:2031-8.
7. Juge PA, Crestani B, Dieudé P. Recent advances in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Pulm Med 2020;26:477-86.
8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
9. Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications. Respir Res 2013;14:9921-14.
10. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA 2018;320:2020.
11. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology 2017;56:344-50.
12. Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit 2015;21:708-15.
13. Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 2014;9:e92449.
14. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2017;36:817-23.
15. Wang T, Zheng XJ, Ji YL, Liang ZA, Liang BM. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol 2016;34:587-91.
16. Kamiya H, Panlaqui OM. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 2021;11:e040465.
17. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004;232:81-91.
18. Sparks JA, Karlson EW. The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis. Curr Rheumatol Rep 2016;18:15.
19. Gizzinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT, Brown KK, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009;28:611–3.
20. Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996;39:1711-9.
21. Rojas-Serrano J, Mejia M, Rivero-Matias PA, Herrera-Bringas D, Perez-Roman DJ, Perez-Dorame R, et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis. Clin Rheumatol 2022;41:1741-7.
22. Pérez-Dórame R, Mejia M, Mateos-Toledo H, Rojas-Serrano J. Rheumatoid arthritis-associated interstitial lung disease: Lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clin 2015;11:12-6.
23. Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 2010;49:1483–9.
24. Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tudor R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013;107:1247–52.
25. Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A, et al. Incidence of and risk factors for interstitial lung disease associated to anti-cyclic citrullinated peptide (CCP) autoantibodies in patients with rheumatoid arthritis. Mod Rheumatol 2018;28:456-63.
26. Restrepo JF, del Rincón J, Battaforano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol
27. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: Clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998;157:1658-65.
28. Ibfelt EH, Jacobsen RK, Kopp T, Cordtz RL, Jakobsen AS, Seersholm N, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology 2021;60:346-52.
29. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014;66:803-12.
30. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev 2021;30:210011.
31. Carrasco Cubero C, Chamizo Carmona E, Vela Casasempere P. Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis. Reumatol Clin (Engl Ed) 2021;17:504-13.